Introduction
Large clinical trials have shown that dual antiplatelet therapy (aspirin plus clopidogrel) reduces the risk of recurrent cardiovascular events in patients with coronary artery disease (CAD). 1 Recently, however, studies have reported that the response to clopidogrel varies between individuals. Resulting in an ineffective response in a consistent proportion of patients. [2] [3] [4] In addition, it has been shown by some clinical studies that the presence of high ontreatment platelet reactivity is, in actual fact, an independent predictor of adverse outcome in patients with CAD, undergoing dual antiplatelet treatment. 5, 6 The phenomenon of the high on-treatment platelet reactivity in spite of the clopidogrel therapy is likely to be related to several mechanisms including clinical factors, patients' non-compliance and pharmacokinetics. However, evidence has revealed a striking relevance for polymorphisms in genes encoding different platelet components, as well as enzymes involved in drug metabolism and function, because of its possible relevant role in determining individual susceptibility to the antiplatelet drug response. 7 Clopidogrel is a prodrug requiring oxidation by the hepatic cytochrome P450 (CYP450) system to generate an active thiol metabolite, which then selectively and irreversibly binds to the P2Y12 receptor on the platelet membrane. Actually, several polymorphisms in genes encoding platelet components (for example, P2Y12 gene) or CYP450 enzyme isoforms (CYP2C19, CYP1A2, CYP2B6, CYP2C9 and CYP3A4 genes) have been proposed [7] [8] [9] but only the loss-of-function CYP2C19*2 has been consistently associated with blunted antiplatelet response to clopidogrel. 7, 10 The CYP2C19*2 polymorphism is a G681A nucleotide substitution at the junction of intron 4 and exon 5, which introduces a splicing defect resulting in a truncated, non-functional protein, responsible for the poor metabolizer phenotype.
During the last few years, some studies have investigated the possible association between such a polymorphism and clinical recurrences, by evidencing in most, but not in all of them, a significant association between the presence of the variant allele *2 and the occurrence of recurrent atherothrombotic events in patients with CAD. [11] [12] [13] [14] [15] [16] [17] The aim of this study was to conduct a systematic review with metaanalysis of all the published prospective cohort studies that have investigated CYP2C19*2 polymorphism in relation to adverse clinical outcome in CAD patients who were undergoing clopidogrel treatment.
Materials and methods
Reports containing information on the relationship between CYP2C19*2 polymorphism and cardiovascular disease were identified through a computerized search in all the electronic databases: MedLine (source PubMed, 1966 to January 2010), Embase (1980 to January 2010), Web of Science, The Cochrane Library (source The Cochrane Central Register of Controlled Trials, 2009, issue 1) and Google Scholar using the following text and key words in combination as MeSH terms and text words: 'clopidogrel', 'plavix', 'iscover', 'cytochrome', 'polymorphism' and 'gene' with 'outcome', 'stent thrombosis', 'cardiovascular disease', 'cardiovascular events', 'adverse events', 'major adverse cardiovascular events' and 'recurrences'. The search strategy had no language restrictions and was supplemented by manually reviewing the reference list of all retrieved articles as well as abstracts from major cardiovascular meetings from recent years.
Two investigators (FS, BG) assessed potentially relevant articles for eligibility. The decision to include or exclude studies was hierarchical and initially made on the basis of the study title, then the study abstract, and finally the complete study paper. In the event of conflicting opinions, resolution of the disagreement was reached through discussion, with the help of a third investigator (RM). Eligible studies were included if they met all of the following criteria: (i) evaluation of the CYP2C19*2 polymorphism using prospective design; (ii) contained non-overlapping data; (iii) data relevant to the calculation of the size and variance of the effect; and (iv) evaluation of CAD patients on antiplatelet treatment.
The main endpoint of the study was to evaluate the influence of the *2 variant of the CYP2C19 gene on the occurrence of cardiovascular recurrences. To this end, we tested a dominant model, in which the carriers of the rare allele were compared with those homozygous for the wild-type allele (*1/*2 þ *2/*2 vs *1/*1). This is due to the following reasons: (i) we avoided multiple comparisons inflating type I error; and (ii) the low frequency of homozygosity for variant allele would generate unreliable estimates of association.
Outcomes of interest for the current meta-analysis were major adverse cardiovascular events-defined as any cardiovascular event (fatal and non-fatal myocardial infarction, stroke, unstable angina), death from cardiovascular causes, ischemic recurrences, stent thrombosis and death from any causes occurred during follow-up.
Data extraction
All data were reviewed and separately extracted by two independent investigators (FS, BG) using a standardized format. The following baseline characteristics for patients were collected: number of patients, age, type of disease, clopidogrel dosages, primary outcomes of the study, genotype distribution, estimates of associations and adjustment for confounding factors.
Statistical analysis
We used Review Manager (RevMan; version 5.0 for Macintosh; Oxford, UK; The Cochrane Collaboration, 2003) to pool results from the individual studies. Pooled results are reported as hazard ratio or odds ratio and are presented with 95% confidence interval (CI) with two-sided P-values using a fixed-effects model (Mantel-Haenszel method); these findings were compared with results obtained using a random-effects model (DerSimonian and Laird method). Hazard ratio and odds ratio were assumed to represent nearly the same relative risk and are collectively described as risk ratios (RRs). A P-value o0.05 was considered statistically significant. The results of the original studies, using multivariate models with the most complete adjustment for potential confounders, were used when available; the confounding variables included in these analyses are shown in Table 1 . When not provided, such as for the studies by Trenk et al., 11 and by Simon et al. 12 estimates of association were calculated using the number of Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences Only patients who were still taking clopidogrel after 1 year.
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences patients with high on-treatment platelet reactivity who experienced major adverse cardiovascular events as reported in the paper, by using conventional procedures. Statistical heterogeneity was evaluated using the I 2 statistic, which assesses the appropriateness of pooling the individual study results. The I 2 value provides an estimate of the amount of variance across studies because of the heterogeneity rather than chance. Where I 2 was 450%, heterogeneity was considered substantial. Funnel plots of effect size against standard error were examined, whenever possible, to assess for the presence of publication bias.
Results

Study identification and selection
Our search strategy yielded 65 reports; of them 52 were excluded on the basis of title/abstract. Of the remaining 13 articles, four papers were excluded because they did not evaluate the polymorphism of interest to the current metaanalysis, and two studies were eliminated because they had no prospective design.
Hence, seven prospective cohort studies were ultimately included in the meta-analysis giving a total number of 8043 patients followed for a period ranging from 1 month to 8.3 years.
The characteristics of the studies included in the metaanalysis are summarized in Table 1 . Interestingly, all of the studies but one have been conducted in European countries, within the last year. Patients enrolled in those studies included comprised ones with acute coronary syndromes or stable CAD. Half of the studies included (three out of six) used a loading dose of 600 mg of clopidogrel, two studies had a loading dose of 300 mg and one did not report any loading dose. For the remaining study, both dosages were used. In contrast, all of the studies reported a maintenance dose of 75 mg day -1 of clopidogrel.
The primary outcomes for the studies included were overall mortality, mortality by cardiovascular causes, major adverse cardiovascular events and stent thrombosis. In only four out of seven studies statistical analysis was adjusted for confounding variables.
Meta-analysis
The summary RR under a fixed-effects model showed that patients carrying the CYP2C19*2 allele had an increased risk of a subsequent cardiovascular event in spite of the clopidogrel treatment (1.33, 95% CI 1.09-1.61; P ¼ 0.004). Although there was significant statistical heterogeneity across the studies (Po0.0001; I 2 ¼ 81%), the random-effects model yielded a similar estimate of increased risk (RR: 1.96, 95% CI 1.14-3.37; P ¼ 0.02) (Figure 1) . Furthermore, statistical heterogeneity was no longer evident (P ¼ 0.9; I 2 ¼ 0%) when the studies by Trenk et al., 11 Simon et al. 12 and Mega et al., 14 which accounted for the heterogeneity of the model, were excluded from the analysis. At the same time, these three studies did not adjust statistical analyses for any of the possible confounding factors. The funnel plot of effect size vs standard error performed to investigate for a possible publication bias, was shown to be slightly asymmetric, suggesting the presence of some statistical outliers among the studies included (Figure 2 ).
In addition, we performed the analysis to investigate the possible relationship between CYP2C19*2 allele and increased risk of stent thrombosis (Figure 3 ). When studies with stent thrombosis as the primary outcome (n ¼ 4) for a total of 4975 patients were considered, the presence of the CYP2C19*2 variant allele was associated with an increased risk of stent thrombosis (RR: 3.82, 95% CI 2.23-6.54; Po0.00001), with no statistical heterogeneity across the studies (P ¼ 0.9; I 2 ¼ 0%). Finally, we performed some sensitivity analyses by grouping studies with similar characteristics (loading dose of Figure 1 Risk of cardiovascular recurrences for patients carrying CYP2C19*2 allele. For the studies by Simon et al. 11 and Trenk et al., 11 estimates of associations were calculated from data taken from the original paper.
Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences clopidogrel, adjustment for confounders, duration of followup above the median time of follow-up). Significant differences, in terms of an increased risk of adverse cardiovascular events, between studies that reported an adjustment for potential confounders (n ¼ 4; RR: 3.85, 95% CI 2.41-6.15; Po0.00001) and those which did not adjust their statistical analyses (n ¼ 3; RR: 1.06, 95% CI 0.67-1.67; P ¼ 0.9) have been reported. Similarly, studies lasting for o1 year (n ¼ 2; RR: 3.26, 95% CI 1.59-6.67; P ¼ 0.001) showed a more significant association with adverse cardiovascular events when compared with those with a longer duration (n ¼ 5; RR: 1.67, 95% CI 0.91-3.08; P ¼ 0.1), whereas no significant differences for different loading doses of clopidogrel have been observed.
Discussion
The present meta-analysis performed in seven cohort prospective studies, with information from an overall incorporated population of more than 8000 patients with CAD undergoing dual antiplatelet treatment and 470 Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences F Sofi et al incident cases that occurred over a follow-up time ranging from 1 month to 8.3 years, provides the first comprehensive assessment so far of the association between CYP2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel. Indeed, patients carrying the *2 variant allele of the polymorphism in question are modestly associated with an increased risk of a future atherothrombotic event and stent thrombosis in spite of the antiplatelet treatment.
This result seems to be influenced by the duration of treatment, being higher in studies with a follow-up duration of o1 year with respect to those with a duration of 41 year, and by the statistical adjustments for confounding factors, that is, not being statistically significant in studies that did not adjust the final analysis for confounding factors such as traditional cardiovascular risk factors, or age.
Indeed, in patients with CAD dual antiplatelet treatment with aspirin and clopidogrel is the standard care for preventing life-threatening cardiovascular recurrences. 1 In spite of this treatment, however, a consistent proportion of patients on dual antiplatelet therapy still manifest atherothrombotic events with possible severe clinical consequences.
2-4 High on-treatment platelet reactivity has, in fact, recently been shown, by some studies and metaanalyses, to be associated with more frequent adverse events in CAD patients who underwent percutaneous coronary intervention with stent placement. 5, 6, 11 High on-treatment platelet reactivity can be because of several factors, including polymorphisms in genes that encode isoforms of cytochrome P450, an enzyme involved in the biotransformation of clopidogrel into its active metabolite. Indeed, clopidogrel is a pro-drug converted to its active thiol metabolite (SR26334) in two sequential oxidation steps, both occurring in the liver, by the hepatic CYP450. 18, 19 To date, conflicting findings on the causal involvement of the CYP450 enzyme CYP2C19 in the biotransformation of clopidogrel to its active metabolite are available. CYP2C19 does not appear to contribute to the biotransformation of clopidogrel, when incubating clopidogrel with human microsome preparation expressing CYP2C19. 20 Moreover, data from an as yet unpublished study, the COGENT randomized controlled study, which compared the effects of omeprazole, a potent CYP2C19 inhibitor, vs a placebo, on the clinical outcome in patients treated with clopidogrel, showed that omeprazole had no effect on the clinical performance of clopidogrel. 21 On the contrary, just recently, it has been shown that several CYP450 enzyme isoforms, with different contributions, are responsible for the oxidation of the thiophene ring of clopidogrel to 2-oxoclopidogrel (first oxidation step: CYP1A2, 35.8%; CYP2B6, 19.4%; and CYP2C19, 44.9%), which is further oxidized (second oxidation step: CYP2B6, 32.9%; CYP2C9, 6.76%; CYP2C19, 20.6%; and CYP3A4, 39,8%), resulting in the opening of the thiophene ring and the formation of both a carboxyl and a thiol group. 22 Therefore, according to these data, among the different CYP450 isoenzymes involved in clopidogrel metabolism, CYP2C19 seems to contribute substantially to both oxidative steps of the clopidogrel conversion to its active metabolite, which explains the pivotal role of genetic polymorphisms in the gene responsible for coding these enzyme isoforms.
Over the last few years, increasing clinical interest in the CYP2C19*2 polymorphism has been reported. In 2007, we were able to show, 7 for the first time in a large cohort of patients undergoing elective coronary interventions that carriers of the *2 allelic variant of the CYP2C19 polymorphism were associated with a higher risk of high ontreatment platelet reactivity. However, although some studies have shown the influence of such a genetic variant on platelet response to clopidogrel, clinical data on the relevance of this polymorphism to the risk of secondary atherothrombotic events remains limited. Few studies, and all published within the last 2 years, have hypothesized this pathogenetic relationship, [11] [12] [13] [14] [15] [16] [17] with conflicting findings. Indeed, Trenk et al. 11 did not show any significant association with cardiovascular recurrences in a follow-up period of 1 year, the study by Simon et al. 12 have shown an association only when any variant alleles among the several genetic polymorphisms investigated were analyzed all together but not specifically with the CYP2C19*2 one, while the study by Mega et al., 14 Collet et al. 13 and Shuldiner et al. 17 have shown a significant association with the clinical outcome. In addition, a recent large study of Sibbing et al., 15 has confirmed the clinical association between such a polymorphism and the occurrence of stent thrombosis while even more recently our study has shown a clinical association between CYP2C19*2 allele and an increased risk of stent thrombosis in a large group of Italian patients. 16 To date, besides the CYP2C19*2, other less common lossof-function polymorphisms in the CYP2C19 gene have been investigated for a possible contribution to determining the poor metabolizer phenotype, such as CYP2C19*4 and CYP2C19*5. However, even when the contribution of these rare alleles was estimated together with the *2 type, such as in the study by Simon et al., 12 nearly 97% of the detected loss-of-function alleles remained ascribed to the *2 type.
To the best of our knowledge, this is the first meta-analysis that has attempted to analyse all of these recent studies in the search of the possible clinical relevance of this polymorphism in such a group of high-risk patients. The major result of the present meta-analysis is that patients who carry at least one CYP2C19*2 allele have a moderately higher risk of a recurrent cardiovascular event, as compared with CYP2C19*1 wild-type homozygous patients.
Another striking finding of the present meta-analysis is the significant association found between CYP2C19*2 allele and the increased risk of stent thrombosis. Stent thrombosis is a life-threatening event; it has been recently shown that stent thrombosis can be determined by an attenuate metabolism of clopidogrel into its active thiol metabolite. 23 The result of the present meta-analysis supports the findings of previous studies, showing that the conversion of clopidogrel into its active compound is significantly decreased in patients with stent thrombosis when compared with healthy controls. 24 The presence of the CYP2C19*2 allele is, Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in fact, able to determine an altered metabolism of clopidogrel, thus possibly increasing the risk of stent thrombosis in the follow-up period after percutaneous coronary intervention with stent implantation. Moreover, stent thrombosis is more likely to be affected by the inadequate deactivation of the platelet activity determined by the CYP2C19*2 polymorphism, with respect to the combined endpoint, including fatal and non-fatal myocardial infarction, unstable angina, stroke and deaths from any causes, whose pathogenetic mechanisms are more intricate. In addition, the observation that studies with a shorter follow-up duration showed a more robust association with adverse clinical events, compared with those with a longer duration, is consistent with the higher association found with stent thromboses, a clinical event that tends to occur earlier after the acute event.
However, several potential limitations of this study should be considered. First of all, because of the nature of the meta-analysis that has been conducted among published studies and not on individual patients' data, we were not able to obtain information on some of the relevant issues, such as different clinical end-points, comorbidities or concomitant therapies. Furthermore, the inclusion of only published studies did not allow us to exclude the possibility that publication bias is present in the literature context of this issue. In contrast, a formal funnel plot test showed the possibility that publication bias could be present in our meta-analysis, and that a significant heterogeneity exists among the included studies, possibly because of the differences in terms of patient type, clopidogrel dosages and statistical analyses. Indeed, the drawbacks of systematic reviews with meta-analyses are well known and include the evident potential for small study bias, moderate statistical inconsistency and the large heterogeneity existing among the included studies, especially when the number of studies is not so large. However, subgroup analyses have shown that after exclusion of some outliers the significant heterogeneity across the studies disappeared.
In conclusion, our data reveal the special role of CYP2C19*2 polymorphism in the occurrence of subsequent cardiovascular events in patients with CAD udnergoing dual antiplatelet treatment, even if the evidence available is limited by some potential biases. This finding could be of relevance especially in light of the relatively high number of patients with CAD being treated with the dual antiplatelet treatment. If confirmed by further studies, this finding could be a promising approach for the calculation of the global risk burden of such patients with regard to the prevention of life-threatening events after the acute event.
